Today I’m joined by Rich Daly, CEO of Catalyst Pharmaceuticals — one of the standout rare-disease success stories in the industry and recently named one of America’s most successful small-cap companies by Forbes.

Rich has spent more than 25 years leading organisations across biotech and pharma — including AstraZeneca, BeyondSpring, CARsgen, and others — and now he’s steering Catalyst as they expand their portfolio, grow their footprint, and continue delivering life-changing treatments for patients with rare neuromuscular and neurological diseases.

We talk about what drew him to Catalyst, how the company thinks about growth, patient service, and rare-disease strategy, how they find the right drugs in a competitive market, and how Catalyst continues to outperform despite the volatility across biotech.

Let’s get into it.